International Conference on Oncology and Cancer Research

Introduction of Oncology conferences

The International Conference on Oncology and Cancer Research is an event that brings together researchers, healthcare professionals, and experts from the field of oncology and cancer research to discuss the latest developments and advancements in the field. The conference provides a platform for sharing new ideas, scientific knowledge, and research findings among the participants. The conference usually includes keynote speeches, plenary sessions, oral presentations, poster sessions, and workshops. The conference topics may include, but are not limited to, the following areas of cancer research: Basic cancer research, Clinical trials and studies, Cancer prevention and early detection, Cancer diagnosis and treatment, Cancer therapies and new treatments,Cancer epidemiology and statistics, Cancer informatics and technology, Cancer rehabilitation and palliative care, Cancer policy and advocacy. The International Conference on Oncology and Cancer Research is an opportunity for professionals from various backgrounds to come together and collaborate on ways to improve the diagnosis, treatment, and overall management of cancer.

Theme: Exploring the Recent Research and Advancements in Oncology

Theme

International Conference on Oncology and Cancer Research

Theme: Exploring the Recent Research and Advancements in Oncology

Objectives

To bring together experimenters, clinicians, and healthcare professionals to partake the rearmost advances in oncology and cancer exploration.

To foster interdisciplinary collaborations and hookups between academic, clinical, and assiduity experimenters to advance the field of oncology and cancer exploration.

To give a platform for the dispersion of new exploration findings, methodologies, and technologies in the field of oncology and cancer exploration.

To encourage the exchange of ideas and gests between experimenters, clinicians, and healthcare professionals from different regions and countries.

To give openings for youthful investigators and scholars to present their exploration and interact with established experimenters in the field.

To promote the restatement of scientific discoveries into clinical operations and patient care.

To address crucial challenges and openings in the field of oncology and cancer exploration, similar to an individualized drug, immunotherapy, and the development of new remedial strategies.

To promote public mindfulness and education about cancer exploration and its impact on society.

Organizers

Pencis publishes original research papers, review papers and management reports, conference publications, thesis, videos, books, and news on various themes of scientific research. Articles Published in our Open Access Journals are Peer Reviewed. We establish our Relationship with the scholars and the Universities through various activities such as seminars, workshops, conferences, and Symposia. We are a decisive, conclusive & fast-moving company open to new ideas and ingenious publishing. We also preserve long-term relationships with our authors and support them throughout their careers. We acquire, develop and distribute knowledge by disseminating scholarly and professional materials around the world. All  Journals published by us maintain the highest standards of quality, with Editorial Boards composed of scholars & Experts from around the world.

Dates and location

International Conferences on Oncology and Cancer Research, organized by Pencis group

14th Edition of Oncology Summit | 24-26 April 2023 | London, United Kingdom
15th Edition of Oncology Summit | 20-22 June 2023 | San Francisco, United States
16th Edition of Oncology Summit | 21-23 August 2023 | Berlin, Germany
17th Edition of Oncology Summit | 16-18 October 2023 | Paris, France
18th Edition of Oncology Summit | 04-06 December 2023 | Dubai, United Arab Emirates

Call for Abstract

Original Articles/papers are invited from Industry Persons, Scientist, Academician, Research Scholars, P.G. & U.G. Students for presentation in our International Conference. All articles/papers must be in MS-Word (.doc or .docx) format, including the title, authors name, affiliation of all authors, e-mail, abstract, keywords, Conclusion, Acknowledgement, and References.

Submit Abstract

The Candidates with eligibility can click the "Submit Paper/Abstract Now" button and fill up the online submission form and Submit.

Abstract/Full Paper submission

Final/Full Paper submission is optional: If you don't want your Abstract/full paper to be published in the Conferences Abstracts & Proceedings CD (with ISBN number) and only want to present it at the conference, it is acceptable.

Page limit: There is a limit of 6-8 pages for a final/full paper. Additional page is chargeable.

Paper language: Final/Full papers should be in English.

Templates: "Final paper template," "Final abstract template"

All the final papers should be uploaded to website online system according to "the final paper template" as word doc. or docx, since this will be the camera ready published version. Please note that final papers that are not uploaded to online System as a word doc./docx after the opening of final paper submissions according to the template above will not be published in the CONFERENCE Abstracts & Proceedings CD (with ISBN number)

Journal Publication

All accepted papers will be included in the conference proceedings, which will be published in one of the authors prescribed Pencis journals.

Registration Procedure

• Click the “Register Now” button at the conference page and enter your Submission ID in the Search Box
• Your Submissions will be listed on that page. You can find the Register Now link beside your submission. Click the link, and now you will be redirected to the Conference registration form where you can make your registration using credit/debit cards
• The Fee charged for E-Poster is to display the E-Posters only on the Website. The Abstract will be published in the conference proceeding book.

Registration Types

Speaker Registration

• Access to all event Session
• Certificate of Presentation
• Handbook
• Conference Kit
• Tea, Coffee & Snack,
• Lunch during the Conference
• Publication of Abstract /Full Paper at the Conference Proceedings Book
• Opportunity to give a Keynote/ Poster Presentations/ Plenary/ Workshop
• Opportunity to publish your Abstract in any of our esteemed Journals discounted rate
• Opportunity to publish your full article in our open access book with a discounted rate
• One to One Expert Forums

Delegate (Participant) Registration

• Access to all Event Sessions
• Participation Certificate
• Handbook
• Conference Kit
• Tea, Coffee & Snack,
• Lunch during the Conference
• Delegates are not allowed to present

Poster Registration

• Includes all the above Registration Benefits
• You will have to bring your Posters to the Conference Venue
• Best poster award memento and certificate on stage.

Poster Guidelines

• The poster should be 1×1 m Size.
• The title, contents, text, and the author’s information should be visible.
• Present numerical data in the form of graphs rather than tables.
• Figures make trends in the data much more evident.
• Avoid submitting high word-count posters.
• Poster contains, e.g., Introduction, Methods, Results, Discussion, Conclusions, and Literature.

Research Forum (Awards)

• Includes all the above Registration Benefits.
• The attendee should be required age limit.
• Award memento and certificate on stage.

E-Poster Presentation

• The amount charged for E-Posters is to display the E-Posters only on the website
• The presenter will get an e-poster participation certificate as a soft copy
• The abstract will be published in the particular journal and also in the conference proceeding book
• The presenter is not required to be present in person at the Conference

Video Presentation

• The amount charged for Video Presentation is to display the Presentation at the Conference.
• The presenter will get a Video participation certificate as a soft copy
• The abstract will be published in the particular journal and also in the conference proceeding book
• The presenter is not required to be present in person at the Conference

Accompanying Person

• Accompanying Persons are those who attend the participants at the Conference who may be either a spouse/family partner or a son/daughter and must register under this category.
• Please note that business partners do not qualify as Accompanying Persons and are not allowed to register as an Accompanying Person.

List of Committee Members

Details of Conference Awards

Pencis awards the Researchers and Research organizations around the world in the motive of Encouraging and Honouring them for their Significant contributions & Achievements for the Advancement in their field of expertise. Researchers and scholars of all nationalities are eligible to receive Pencis Research awards. Nominees are judged on past accomplishments, research excellence, and outstanding academic achievements

Award Categories

Best Poster Award

Posters will be evaluated based on Presentation Style, Research Quality, and Layout/Design. Unique opportunity to combine visual and oral explanations of your projects in the form of poster presentation. Posters should have the Title (with authors affiliation & contact details), Introduction, Methods, Results (with tables, graphs, pictures) Discussion, Conclusion, References, and Acknowledgements. The size of the poster should be: 1mX1.5m; Text:16-26 pt; Headings: 32-50 pt; Title: 70 pt; Color: Preferable. Bring your poster to the meeting, using tubular packaging. Presenting duration: 10 min discussion & 5 min query per person. Eligibility: The presenter can nominate for the Award. He must be under 40 years of age as on the conference date.

Best Presentation Award

The presentation will be evaluated based on Presentation Style, Research Quality, and Layout/Design. Unique opportunity to combine visual and oral explanations of your projects in the form of poster presentation. The presentation should have the Title (with authors affiliation & contact details), Introduction, Methods, Results (with tables, graphs, pictures) Discussion, Conclusion, References, and Acknowledgements. Bring your presentation to the meeting, using a pen drive. Presenting duration: 10-20 min discussion & 5 min query per person. Eligibility: The presenter can nominate for the Award. He must be under 55 years of age as on the conference date.

Best Paper Award

Paper will be evaluated based on Format, Research Quality, and Layout/Design. The paper should have the Title (with authors affiliation & contact details), Introduction, Methods, Results (with tables, graphs, pictures) Discussion, Conclusion, References, and Acknowledgements. Eligibility: The presenter can nominate for the Award. He must be under 55 years of age as on the conference date.

Instructions for submission

If you want to submit only your Abstract

• If you want to publish only your abstract (it is also optional) in the CONFERENCE Abstracts & Proceedings CD (with ISBN number), upload your abstract again according to the final abstract template as word doc. or Docx.
• If you also don't want your abstract to be published in the CONFERENCE Abstracts & Proceedings CD (with an ISBN number) and only want to present it at the conference, it is also acceptable

How to Submit your Abstract / Full Paper

Please read the instructions below then submit your Abstract/ Full Paper (or just final abstract) via online conference system:

• STEP 1: Please download the Abstract /Final Paper Template and submit your final paper exactly according to the template: International Conference on Oncology and Cancer Research Final Paper Template word format (.doc /.docx). See a final abstract template formatted according to the template.
• STEP 2: Please assure that the Abstract/ full paper follows exactly the format and template as described in the final paper template document below since this will be the camera-ready published version. All final papers should be written only in English and “word document" as .doc or .docx format.
• STEP 3: You can submit your final paper(s) to the online conference system only by uploading/ Re-submission your current submission.
• STEP 4: After logging/using submission ID in the online conference system, click on the "Re-submission" link at the bottom of the page.
• STEP 5: After the "Resubmission page" opens, upload your abstract/ final paper (it should be MS word document -doc. or Docx-).

General Information

• Dress Code: Participants have to wear a formal dress. There are no restrictions on Color or design. The audience attending only the ceremony can wear clothing of their own choice.
• Certificate Distribution: Each presenter's name will be called & asked to collect their certificate on the Stage with an official photographer to capture the moments.

Pencis Terms & Conditions

International Conference on Oncology and Cancer Research Terms & Conditions Policy was last updated on June 25, 2022.

Privacy Policy

International Conference on Oncology and Cancer Research Customer personal information for our legitimate business purposes, to process and respond to inquiries, and provide our services, to manage our relationship with editors, authors, institutional clients, service providers, and other business contacts, to market our services and subscription management. We do not sell, rent/ trade your personal information to third parties.

Relationship

International Conference on Oncology and Cancer Research Operate a Customer Association Management and email list program, which we use to inform customers and other contacts about our services, including our publications and events. Such marketing messages may contain tracking technologies to track subscriber activity relating to engagement, demographics, and other data, and to build subscriber profiles.

Disclaimer

International Conference on Oncology and Cancer Research All editorial matter published on this website represents the opinions of the authors and not necessarily those of the Publisher with the publications. Statements and opinions expressed do not represent the official policies of the relevant Associations unless so stated. Every effort has been made to ensure the accuracy of the material that appears on this website. Please ignore, however, that some errors may occur.

Responsibility

International Conference on Oncology and Cancer Research Delegates are personally responsible for their belongings at the venue. The Organizers will not be held accountable for any stolen or missing items belonging to Delegates, Speakers, or Attendees; due to any reason whatsoever.

Insurance

International Conference on Oncology and Cancer Research Registration fees do not include insurance of any kind.

Press and Media

Press permission must be getting from the International Conference on Oncology and Cancer Research Organizing Committee before the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. This conference is not associated with any commercial meeting company.

Transportation

International Conference on Oncology and Cancer Research Please note that any (or) all traffic and parking is the responsibility of the registrant.

Requesting an Invitation Letter

International Conference on Oncology and Cancer Research For security purposes, the letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact contact@Pencis.com to request a personalized letter of invitation.

Cancellation Policy

If International Conference on Oncology and Cancer Research cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another International Conference on Oncology and Cancer Research event which must occur within one year from the date of cancellation.

Postponement Policy

If International Conference on Oncology and Cancer Research postpones an event for any reason and you are unable or indisposed to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another International Conference on Oncology and Cancer Research which must occur within one year from the date of postponement.

Transfer of registration

International Conference on Oncology and Cancer Research  All fully paid registrations are transferable to other persons from the same organization if the registered person is unable to attend the event. The registered person must make transfers in writing to contact@Pencis.com. Details must include the full name of alternative person, their title, contact phone number, and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Pencis if the person is unable to attend one of the meetings. However, Registration cannot be transferred if it will intimated within 14 days of the particular conference. The transferred registrations will not be eligible for Refund.

Visa Information

International Conference on Oncology and Cancer Research Keeping given increased security measures, we would like to request all the participants to apply for Visa as soon as possible. Pencis will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only. Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Pencis, including the inability to obtain a visa.

Refund Policy

International Conference on Oncology and Cancer Research Regarding refunds, all bank charges will be for the registrant's account. All cancellations or modifications of registration must make in writing to oncology@pencis.com

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping given advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following conditions,

• Before 60 days of the Conference: Eligible for Full Refund less $100 Service Fee
• Within 60-30 days of Conference: Eligible for 50% of payment Refund
• Within 30 days of Conference: Not eligible for Refund
• E-Poster Payments will not be refunded.

Accommodation Cancellation Policy

International Conference on Oncology and Cancer Research Accommodation Providers such as hotels have their cancellation policies, and they generally apply when cancellations are made less than 30 days before arrival. Please contact us as soon as possible if you wish to cancel or amend your accommodation. Pencis will advise the cancellation policy of your accommodation provider, before withdrawing or to changing your booking, to ensure you are fully aware of any non-refundable deposits.

Related Journals

1.Journal of Clinical Oncology (United States): This journal was first published in 1983 and has an impact factor of 32.956 (2020) | 2.Cancer Research (United States): This journal was first published in 1941 and has an impact factor of 10.211 (2020) | 3.Annals of Oncology (Europe): This journal was first published in 1990 and has an impact factor of 18.142 (2020) | 4.Lancet Oncology (United Kingdom): This journal was first published in 2000 and has an impact factor of 36.420 (2020) | 5.Nature Reviews Cancer (United Kingdom): This journal was first published in 2001 and has an impact factor of 49.516 (2020) | 6.Cancer Cell (United States): This journal was first published in 2002 and has an impact factor of 27.407 (2020) | 7.Clinical Cancer Research (United States): This journal was first published in 1995 and has an impact factor of 11.228 (2020) | 8.Cancer Discovery (United States): This journal was first published in 2011 and has an impact factor of 34.188 (2020). | 9.Cancer (United States): This journal was first published in 1948 and has an impact factor of 6.762 (2020). | 10. Journal of the National Cancer Institute (United States): This journal was first published in 1940 and has an impact factor of 14.164 (2020) | 11. cancer Cell International (United Kingdom): This journal was first published in 2001 and has an impact factor of 5.008 (2020) | 12. Molecular Cancer (United Kingdom): This journal was first published in 2002 and has an impact factor of 13.816 (2020) | 13. Journal of Hematology & Oncology (United Kingdom): This journal was first published in 2008 and has an impact factor of 10.850 (2020). | 14. Cancer Immunology Research (United States): This journal was first published in 2013 and has an impact factor of 8.236 (2020). | 15. Journal of the National Comprehensive Cancer Network (United States): This journal was first published in 2003 and has an impact factor of 9.557 (2020). | 16. Cancer Treatment Reviews (United Kingdom): This journal was first published in 1974 and has an impact factor of 8.708 (2020). | 17. Cancer Genetics (United States): This journal was first published in 2010 and has an impact factor of 3.549 (2020). | 18. OncoImmunology (United States): This journal was first published in 2011 and has an impact factor of 7.569 (2020) | 19. Cancer Epidemiology, Biomarkers & Prevention (United States): This journal was first published in 1991 and has an impact factor of 5.508 (2020) | 20. Journal of Cancer Research and Clinical Oncology (Germany): This journal was first published in 1904 and has an impact factor of 6.221 (2020) | 21. Journal of Clinical Oncology (United States): 2021 Impact Factor - 32.956 | 22. Cancer Research (United States): 2021 Impact Factor - 10.259 | 23. Annals of Oncology (Europe): 2021 Impact Factor - 23.590 | 24. Nature Reviews Cancer (United Kingdom): 2021 Impact Factor - 56.521 | 25. Lancet Oncology (United Kingdom): 2021 Impact Factor - 44.964 | 26. Cancer Cell (United States): 2021 Impact Factor - 27.028 | 27. Clinical Cancer Research (United States): 2021 Impact Factor - 11.287 | 28. Journal of the National Cancer Institute (United States): 2021 Impact Factor - 15.885 | 29. Oncogene (United Kingdom): 2021 Impact Factor - 8.729 | 30. Cancer (United States): 2021 Impact Factor - 6.727 | 31. Journal of Clinical Oncology (United States): Impact Factor - 32.956, H-index - 433 | 32. Cancer Research (United States): Impact Factor - 10.259, H-index - 417 | 33. Annals of Oncology (Europe): Impact Factor - 23.590, H-index - 270 | 34. Nature Reviews Cancer (United Kingdom): Impact Factor - 56.521, H-index - 366 | 35. Lancet Oncology (United Kingdom): Impact Factor - 44.964, H-index - 346 | 36. Cancer Cell (United States): Impact Factor - 27.028, H-index - 244 | 37. Clinical Cancer Research (United States): Impact Factor - 11.287, H-index - 292 | 38. Journal of the National Cancer Institute (United States): Impact Factor - 15.885, H-index - 276 | 39. Oncogene (United Kingdom): Impact Factor - 8.729, H-index - 225 | 40. Cancer (United States): Impact Factor - 6.727, H-index - 29 | 41. Journal of Clinical Oncology (United States): Impact Factor - 32.956, H-index - 433 | 42. Cancer Research (United States): Impact Factor - 10.259, H-index - 417 | 43. Annals of Oncology (Europe): Impact Factor - 23.590, H-index - 270 | 44. Nature Reviews Cancer (United Kingdom): Impact Factor - 56.521, H-index - 366 | 45. Lancet Oncology (United Kingdom): Impact Factor - 44.964, H-index - 346 | 46. Cancer Cell (United States): Impact Factor - 27.028, H-index - 244 | 47. Clinical Cancer Research (United States): Impact Factor - 11.287, H-index - 292 | 48. Journal of the National Cancer Institute (United States): Impact Factor - 15.885, H-index - 276 | 49. Oncogene (United Kingdom): Impact Factor - 8.729, H-index - 225 | 50. Cancer (United States): Impact Factor - 6.727, H-index - 295 | 51. European Journal of Cancer (Europe): Impact Factor - 10.824, H-index - 213 |

Related Societies

1.American Association for Cancer Research (AACR) - USA | 2.American Society of Clinical Oncology (ASCO) - USA | 3.European Society for Medical Oncology (ESMO) - Switzerland | 4.European Organisation for Research and Treatment of Cancer (EORTC) - Belgium | 5.International Agency for Research on Cancer (IARC) - France | 6.International Association for the Study of Lung Cancer (IASLC) - USA | 7.International Society for Biological Therapy of Cancer (iSBTc) - USA | 8.International Society of Gynecological Cancer (ISGC) - Belgium | 9.International Society of Oncology Pharmacy Practitioners (ISOPP) - Canada | 10. International Society of Paediatric Oncology (SIOP) - Switzerland | 11. American Cancer Society (ACS) - USA | 12. Association of Community Cancer Centers (ACCC) - USA | 13. Association for Molecular Pathology (AMP) - USA | 14. Association of Oncology Social Work (AOSW) - USA | 15. Australian Cancer Research Foundation (ACRF) - Australia | 16. Australian Society of Medical Research (ASMR) - Australia | 17. British Association of Cancer Research (BACR) - UK | 18. British Gynaecological Cancer Society (BGCS) - UK | 19. British Oncology Pharmacy Association (BOPA) - UK | 20. Cancer Association of South Africa (CANSA) - South Africa | 21. Cancer Research and Biostatistics (CRAB) - USA | 22. Cancer Research Institute (CRI) - USA | 23. Children\'s Cancer and Leukaemia Group (CCLG) - UK | 24. Chinese Anti-Cancer Association (CACA) - China | 25. Chinese Society of Clinical Oncology (CSCO) - China | 26. Deutsche Krebsgesellschaft (DKG) - Germany | 27. Dutch Cancer Society (DCS) - Netherlands | 28. European Association for Cancer Research (EACR) - UK | 29. European Society of Surgical Oncology (ESSO) - Belgium | 30. Finnish Cancer Society (FCS) - Finland | 31. French National Cancer Institute (INCa) - France | 32. German Cancer Research Center (DKFZ) - Germany | 33. German Society of Hematology and Oncology (DGHO) - Germany | 34. German Society for Radiation Oncology (DEGRO) - Germany | 35. German Society of Pediatric Oncology and Hematology (GPOH) - Germany | 36. Greek Society of Oncology (GSO) - Greece | 37. Indian Cancer Society (ICS) - India | 38. Indian Society of Medical and Paediatric Oncology (ISMPO) - India | 39. Institute of Cancer Research (ICR) - UK | 40. International Association for the Study of Cancer (IASC) - Switzerland | 41. International Myeloma Foundation (IMF) - USA | 42. Israel Cancer Association (ICA) - Israel | 43. Italian Association for Cancer Research (AIRC) - Italy | 44. Italian Society of Medical Oncology (AIOM) - Italy | 45. Japanese Society of Clinical Oncology (JSCO) - Japan | 46. Japanese Society of Pediatric Hematology/Oncology (JSPHO) - Japan | 47. Korean Association for Cancer Research (KACR) - South Korea | 48. Korean Cancer Association (KCA) - South Korea |

Popular Books

1.       The Emperor of All Maladies: A Biography of Cancer by Siddhartha Mukherjee, Scribner, 1st edition, 2010. | 2.       Cancer Biology by Robert A. Weinberg, Garland Science, 4th edition, 2020. | 3.       Principles and Practice of Oncology edited by Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg, Wolters Kluwer, 11th edition, 2019. | 4.       Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics by Lauren Pecorino, Oxford University Press, 4th edition, 2020. | 5.       Targeted Therapy of Cancer edited by Stanley P. L. Leong and Mark Faries, Springer, 2nd edition, 2015. | 6.       Essentials of Clinical Radiation Oncology edited by Matthew C. Ward and Rahul D. Tendulkar, Springer, 1st edition, 2019. | 7.       Radiation Oncology: Rationale, Technique, Results by James D. Cox and K. Kian Ang, Mosby, 10th edition, 2016. | 8.       Clinical Oncology edited by Michael J. Peckham, Peter J. Hoskin, and Edward W. C. Newlands, Wiley-Blackwell, 4th edition, 2014. | 9.       Oxford Textbook of Oncology edited by Jim Cassidy, Donald Bissett, and Roy A. J. Spence, Oxford University Press, 4th edition, 2020. | 10.   Atlas of Clinical Oncology: Hodgkin\'s Lymphoma by Joseph M. Connors and Richard T. Hoppe, Springer, 1st edition, 2005. | 11.   The Biology of Cancer by Robert A. Weinberg, Garland Science, 2nd edition, 2013. | 12.   Precision Molecular Pathology of Breast Canceredited by Sunil Badve, George W. Sledge Jr., and David J. Dabbs, Springer, 1st edition, 2015. | 13.   Cancer Drug Resistance edited by Beverly A. Teicher, Humana Press, 2nd edition, 2016. | 14.   Targeting Autophagy in Cancer Therapy edited by Jin-Ming Yang, Springer, 1st edition, 2016. | 15.   Cancer Stem Cells: Methods and Protocols edited by P. Andrew Futreal and Richard P. Hill, Humana Press, 1st edition, 2018. | 16.   Clinical Radiation Oncology by Leonard L. Gunderson and Joel E. Tepper, Elsevier, 4th edition, 2015. | 17.   Radiation Oncology Primer and Review: Essential Concepts and Protocols by Carlos A. Perez, Luis A. Torres-Roca, and Luther W. Brady, Lippincott Williams & Wilkins, 1st edition, 2013. | 18.   Atlas of Gynecologic Oncology Imagingedited by Christine H. Chung and Elizabeth G. Moore, Springer, 1st edition, 2013. | 19.   The Bethesda Handbook of Clinical Oncology edited by Jame Abraham and James L. Gulley, Wolters Kluwer, 5th edition, 2020. | 20.   Breast Imaging: The Requisites by Debra Ikeda and Kanae Kawai Miyake, Elsevier, 3rd edition, 2016. | 21.   Diagnostic Pathology: Breast edited by Susan C. Lester, Amirsys, 2nd edition, 2015. | 22.   Surgical Oncology: A Practical and Comprehensive Approach edited by Raffaele Adamoli, Springer, 1st edition, 2015. | 23.   Handbook of Cancer Chemotherapy edited by Roland T. Skeel and Samir N. Khleif, Lippincott Williams & Wilkins, 8th edition, 2011. | 24.   Cancer Immunotherapy Principles and Practice edited by Lisa H. Butterfield and Howard L. Kaufman, Springer, 1st edition, 2017. | 25.   Principles and Practice of Pediatric Oncology edited by Philip A. Pizzo and David G. Poplack, Lippincott Williams & Wilkins, 7th edition, 2015. | 26.   Atlas of Genitourinary Oncological Imaging edited by Ivan Pedrosa and Jeffrey Cadeddu, Springer, 1st edition, 2013. | 27.   Imaging in Oncology edited by Rakesh K. Gupta and Sumeet Bhargava, Springer, 1st edition, 2011. | 28.   The Molecular Basis of Cancer by John Mendelsohn, Peter M. Howley, and Mark A. Israel, Saunders, 4th edition, 2015. | 29.   Cancer Genetics edited by Christine J. Ye and Janine Seneca, Wiley-Blackwell, 3rd edition, 2016. | 30.   The MD Anderson Manual of Medical Oncology edited by | 31.   The Emperor of All Maladies: A Biography of Cancer by Siddhartha Mukherjee, Scribner, 1st edition, 2010. | 32.   Principles and Practice of Oncology edited by Vincent T. DeVita Jr., Theodore S. Lawrence, and Steven A. Rosenberg, Wolters Kluwer, 11th edition, 2019. | 33.   Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics by Lauren Pecorino, Oxford University Press, 4th edition, 2016. | 34.   Cancer: Principles and Practice of Oncology edited by Vincent T. DeVita Jr., Samuel Hellman, and Steven A. Rosenberg, Lippincott Williams & Wilkins, 10th edition, 2014. | 35.   The Genetic Basis of Human Cancer edited by Bert Vogelstein and Kenneth W. Kinzler, McGraw-Hill Education, 4th edition, 2014. | 36.   Oncology Nursing Review edited by Connie Henke Yarbro, Debra Wujcik, and Barbara Holmes Gobel, Jones & Bartlett Learning, 5th edition, 2017. | 37.   Cancer Immunotherapy: Immune Suppression and Tumor Growth edited by George C. Prendergast and Elizabeth M. Jaffee, Academic Press, 1st edition, 2007. | 38.   Essentials of Clinical Radiation Oncology edited by Matthew C. Ward and Rahul D. Tendulkar, Springer, 1st edition, 2019. | 39.   AJCC Cancer Staging Manual edited by Mahul B. Amin and Stephen B. Edge, Springer, 8th edition, 2017. | 40.   Clinical Oncology edited by Martin D. Abeloff, James O. Armitage, and John E. Niederhuber, Churchill Livingstone, 5th edition, 2013. | 41.   Clinical Radiation Oncology by Leonard L. Gunderson and Joel E. Tepper, Elsevier, 4th edition, 2015. | 42.   Radiation Oncology Primer and Review: Essential Concepts and Protocols by Carlos A. Perez, Luis A. Torres-Roca, and Luther W. Brady, Lippincott Williams & Wilkins, 1st edition, 2013. | 43.   Cancer Stem Cells: Methods and Protocols edited by P. Andrew Futreal and Richard P. Hill, Humana Press, 1st edition, 2018. | 44.   Breast Imaging: The Requisites by Debra Ikeda and Kanae Kawai Miyake, Elsevier, 3rd edition, 2016. | 45.   \"Diagnostic Pathology: Breast\" edited by Susan C. Lester, Amirsys, 2nd edition, 2015. | 46.   \"Surgical Oncology: A Practical and Comprehensive Approach\" edited by Raffaele Adamoli, Springer, 1st edition, 2015. | 47.   Handbook of Cancer Chemotherapy edited by Roland T. Skeel and Samir N. Khleif, Lippincott Williams & Wilkins, 8th edition, 2011. | 48.   Cancer Immunotherapy Principles and Practice edited by Lisa H. Butterfield and Howard L. Kaufman, | 49.   Cancer: Principles and Practice of Oncology edited by Vincent T. DeVita Jr., Theodore S. Lawrence, and Steven A. Rosenberg, Wolters Kluwer, 11th edition, 2019. | 50.   The Emperor of All Maladies: A Biography of Cancer by Siddhartha Mukherjee, Scribner, 1st edition, 2010. | 51.   Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics by Lauren Pecorino, Oxford University Press, 4th edition, 2016. | 52.   Cancer: The Evolutionary Legacy by Mel Greaves, Oxford University Press, 1st edition, 2014. | 53.   The Genetic Basis of Human Cancer edited by Bert Vogelstein and Kenneth W. Kinzler, McGraw-Hill Education, 4th edition, 2014. | 54.   Oncology Nursing Review edited by Connie Henke Yarbro, Debra Wujcik, and Barbara Holmes Gobel, Jones & Bartlett Learning, 5th edition, 2017. | 55.   Cancer Immunotherapy: Immune Suppression and Tumor Growth edited by George C. Prendergast and Elizabeth M. Jaffee, Academic Press, 1st edition, 2007. | 56.   Essentials of Clinical Radiation Oncologynedited by Matthew C. Ward and Rahul D. Tendulkar, Springer, 1st edition, 2019. | 57.   AJCC Cancer Staging Manual edited by Mahul B. Amin and Stephen B. Edge, Springer, 8th edition, 2017. | 58.   Clinical Oncology edited by Martin D. Abeloff, James O. Armitage, and John E. Niederhuber, Churchill Livingstone, 5th edition, 2013. | 59.   Clinical Radiation Oncology by Leonard L. Gunderson and Joel E. Tepper, Elsevier, 4th edition, 2015. | 60.   Radiation Oncology Primer and Review: Essential Concepts and Protocols by Carlos A. Perez, Luis A. Torres-Roca, and Luther W. Brady, Lippincott Williams & Wilkins, 1st edition, 2013. | 61.   Cancer Stem Cells: Methods and Protocols edited by P. Andrew Futreal and Richard P. Hill, Humana Press, 1st edition, 2018. | 62.   Breast Imaging: The Requisites by Debra Ikeda and Kanae Kawai Miyake, Elsevier, 3rd edition, 2016. | 63.   Diagnostic Pathology: Breast edited by Susan C. Lester, Amirsys, 2nd edition, 2015. | 64.   Surgical Oncology: A Practical and Comprehensive Approach edited by Raffaele Adamoli, Springer, 1st edition, 2015. | 65.   Handbook of Cancer Chemotherapy edited by Roland T. Skeel and Samir N. Khleif, Lippincott Williams & Wilkins, 8th edition, 2011. | 66.   Cancer Immunotherapy Principles and Practice edited by Lisa H. Butterfield and Howard L. Kaufman, Demos Medical Publishing, 1st edition, 2017. | 67.   Tumors of the Central Nervous System: Glioma, Meningioma, Neuroblastoma, and Spinal Tum | 68.   \"The Genetic Basis of Human Cancer edited by Bert Vogelstein and Kenneth W. Kinzler, McGraw-Hill Education, 4th edition, 2014. | 69.   Oncogenes and Cancer by D. D. Gillespie and M. B. Eisen, Cold Spring Harbor Laboratory Press, 2nd edition, 2018. | 70.   Cancer Immunotherapy: Immune Suppression and Tumor Growth edited by George C. Prendergast and Elizabeth M. Jaffee, Academic Press, 1st edition, 2007. | 71.   Cancer: The Evolutionary Legacy by Mel Greaves, Oxford University Press, 1st edition, 2014. | 72.   AJCC Cancer Staging Manual edited by Mahul B. Amin and Stephen B. Edge, Springer, 8th edition, 2017. | 73.   Essentials of Clinical Radiation Oncology edited by Matthew C. Ward and Rahul D. Tendulkar, Springer, 1st edition, 2019. | 74.   Clinical Oncology edited by Martin D. Abeloff, James O. Armitage, and John E. Niederhuber, Churchill Livingstone, 5th edition, 2013. | 75.   Molecular Biology of Cancer: Translation to the Clinic by Raymond W. Ruddon, Academic Press, 2nd edition, 2013. | 76.   Principles of Molecular Oncology edited by Miguel H. Bronchud, Susan A. Burchill, and Albert A. Antwi-Baffour, Springer, 2nd edition, 2019. | 77.   Handbook of Cancer Chemotherapy edited by Roland T. Skeel and Samir N. Khleif, Lippincott Williams & Wilkins, 8th edition, 2011. | 78.   Cancer Immunotherapy Principles and Practice edited by Lisa H. Butterfield and Howard L. Kaufman, Demos Medical Publishing, 1st edition, 2017. | 79.   Cancer Genetics and Genomics for Personalized Medicine edited by Il-Jin Kim, Springer, 1st edition, 2016. | 80.   Cancer Epigenetics: Biomolecular Therapeutics for Human Cancer edited by Antonio Giordano and Marcella Macaluso, Wiley-Blackwell, 1st edition, 2011. | 81.   Molecular Targeted Therapy of Lung Cancer edited by Mark A. Socinski and Suresh S. Ramalingam, Springer, 1st edition, 2017. | 82.   Cancer and Aging Handbook: Research and Practice edited by Keith M. Bellizzi, Margot J. Fromer, and Jennifer A. Wargo, Wiley-Blackwell, 1st edition, 2012. | 83.   Cancer Biology\" edited by Raymond W. Ruddon, Oxford University Press, 4th edition, 2016. | 84.   The Molecular Biology of Cancer by Stella Pelengaris and Michael Khan | 85.   Principles and Practice of Oncology by Vincent T. DeVita Jr., Theodore S. Lawrence, Steven A. Rosenberg, Lippincott Williams & Wilkins, 2015 | 86.   Holland-Frei Cancer Medicine by Robert C. Bast Jr., Edward Chu, and Waun Ki Hong, Wiley-Blackwell, 2017 | 87.   Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics by Lauren Pecorino, Oxford University Press, 2019 | 88.   Cancer Epidemiology and Prevention by David Schottenfeld and Joseph F. Fraumeni Jr., Oxford University Press, 2017 | 89.   Targeted Therapy in Translational Cancer Research by Apostolia-Maria Tsimberidou, Springer, 2020 | 90.   Cancer Immunotherapy Principles and Practice by Lisa H. Butterfield and Howard L. Kaufman, Springer, 2020 | 91.   Principles of Cancer Treatment and Therapeutics: The American Society of Clinical Oncology Handbook by Douglas W. Blayney, John Wiley & Sons, 2018 | 92.   The Hallmarks of Cancer: The Next Generation by Douglas Hanahan and Robert A. Weinberg, Cell Press, 2011 | 93.   Cancer: A Very Short Introduction by Nick James, Oxford University Press, 2011 | 94.   Cancer Therapy: Preclinical Models and Clinical Trials by William R. Greco, Springer, 2018 | 95.   Cancer Drug Resistance by Atta-ur-Rahman and Muhammad Iqbal Choudhary, Springer, 2021

Popular Researchers

| 1.Dr. Lisa Coussens, Cancer Biology, Oregon Health & Science University, USA | 2.Dr. Patrick Hwu, Immunotherapy, MD Anderson Cancer Center, USA | 3.Dr. Antoni Ribas, Melanoma and Immunotherapy, UCLA, USA | 4.Dr. James Allison, Cancer Immunology, MD Anderson Cancer Center, USA | 5.Dr. Charles Sawyers, Precision Oncology, Memorial Sloan Kettering Cancer Center, USA | 6.Dr. Elizabeth M. Jaffee, Immunotherapy, Johns Hopkins University, USA | 7.Dr. Axel Ullrich, Molecular Oncology, Max Planck Institute of Biochemistry, Germany | 8.Dr. Carl June, CAR-T Cell Therapy, University of Pennsylvania, USA | 9.Dr. Anton Berns, Genetics of Cancer, Netherlands Cancer Institute, Netherlands | 10. Dr. Daniel Peeper, Tumor Biology, Netherlands Cancer Institute, Netherlands | 11. Dr. Stephen B. Baylin, Epigenetics, Johns Hopkins University, USA | 12. Dr. Mina Bissell, Tumor Microenvironment, Lawrence Berkeley National Laboratory, USA | 13. Dr. Steven A. Rosenberg, Immunotherapy, National Cancer Institute, USA | 14. Dr. Franco Cavalli, Medical Oncology, Oncology Institute of Southern Switzerland, Switzerland | 15. Dr. Eric W. Kaler, Prostate Cancer, University of Minnesota, USA | 16. Dr. Peter K. Vogt, Cancer Genetics, Scripps Research Institute, USA | 17. Dr. Tony Hunter, Signal Transduction, Salk Institute for Biological Studies, USA | 18. Dr. Lewis C. Cantley, Signal Transduction, Weill Cornell Medicine, USA | 19. Dr. Eileen White, Tumor Biology, Rutgers University, USA | 20. Dr. Richard J. Gilbertson, Pediatric Oncology, University of Cambridge, UK | 21. Dr. David Tuveson, Pancreatic Cancer, Cold Spring Harbor Laboratory, USA | 22. Dr. Thomas Tursz, Clinical Research, Gustave Roussy Institute, France | 23. Dr. Hiroshi Nakagawa, Lung Cancer, University of Tokyo, Japan | 24. Dr. Rajesh Chopra, Drug Discovery, Amgen Inc., USA | 25. Dr. Ronald Levy, Lymphoma, Stanford University, USA | 26. Dr. Tak Mak, Immunology, University of Toronto, Canada | 27. Dr. Takashi Tsukamoto, Liver Cancer, Osaka University, Japan | 28. Dr. Gerard Evan, Oncogene Addiction, University of Cambridge, UK | 29. Dr. Elizabeth H. Blackburn, Telomeres, University of California, San Francisco, USA | 30. Dr. Andrew T. Chan, Colorectal Cancer, Harvard Medical School, USA | 31. Dr. Dan Theodorescu, Bladder Cancer, Cedars-Sinai Medical Center, USA | 32. Dr. Ralph Weichselbaum, Radiation Oncology, University of Chicago, USA | 33. Dr. Douglas R. Lowy, Human Papillomavirus (HPV), National Cancer Institute, USA | 34. Dr. Pier Paolo Pandolfi, Tumor Suppressor Genes, Harvard Medical School, USA | 35. Dr. Manuel Hidalgo, Pancreatic Cancer, Beth Israel Deaconess Medical Center, USA | 36. Dr. Paul A. Marks, Tumor Biology, Memorial Sloan Kettering Cancer Center, USA | 37. Dr. Timothy A. Yap, Precision Medicine, University of Texas MD Anderson Cancer Center, USA | 38. Dr. Judah Folkman, Angiogenesis, Harvard Medical School, USA (deceased) | 39. Dr. Bert Vogelstein, Genetics of Cancer, Johns Hopkins University, USA | 40. Dr. Steven Narod, Hereditary Cancer, University of Toronto, Canada | 41. Dr. Jeffery M. Trent, Cancer Genomics, Translational Genomics Research Institute, USA | 42. Dr. Richard D. Klausner, Cancer Detection, GRAIL, USA | 43. Dr. Karen H. Vousden, Tumor Suppressor Genes, Francis Crick Institute, UK | 44. Dr. Peter Campbell, Cancer Genomics, Wellcome Sanger Institute, UK | 45. Dr. Margaret Foti, Cancer Research Policy, American Association for Cancer Research, USA | 46. Dr. Peter C. Adamson, Pediatric Oncology, Children\'s Hospital of Philadelphia, USA | 47. Dr. Max Wicha, Cancer Stem Cells, University of Michigan, USA | 48. Dr. Carolyn Compton, Cancer Biomarkers, Arizona State University, USA | 49. Dr. John Mendelsohn, Targeted Therapy, MD Anderson Cancer Center, USA (deceased) | 50. Dr. Angelika Amon, Chromosome Instability, Massachusetts Institute of Technology, USA | 51. Dr. Michael Stratton, Cancer Genomics, Wellcome Sanger Institute, UK | 52. Dr. Gordon Mills, Precision Oncology, OHSU Knight Cancer Institute, USA | 53. Dr. Anna D. Barker, Cancer Research Strategy, Arizona State University, USA | 54. Dr. Charles L. Sawyers, Precision Oncology, Memorial Sloan Kettering Cancer Center, USA | 55. Dr. Richard L. Schilsky, Clinical Trials, American Society of Clinical Oncology, USA | 56. Dr. Joseph R. Nevins, Genomics and Bioinformatics, Duke University, USA | 57. Dr. John D. Carpten, Cancer Genetics and Health Disparities, University of Southern California, USA | 58. Dr. Lisa M. McShane, Biostatistics, National Cancer Institute, USA | 59. Dr. Elaine R. Mardis, Cancer Genomics, Nationwide Children\'s Hospital, USA | 60. Dr. Michael A. Caligiuri, Immunotherapy, City of Hope, USA | 61. Dr. David J. McConkey, Bladder Cancer, Johns Hopkins University, USA | 62. Dr. Rosalind A. Eeles, Cancer Genetics, The Institute of Cancer Research, UK | 63. Dr. Lisa A. Carey, Breast Cancer, University of North Carolina at Chapel Hill, USA | 64. Dr. Silvia C. Formenti, Radiation Oncology, Weill Cornell Medicine, USA | 65. Dr. Ching-Hon Pui, Pediatric Oncology, St. Jude Children\'s Research Hospital, USA | 66. Dr. Olli Kallioniemi, Precision Oncology, Karolinska Institutet, Sweden | 67. Dr. Roman Perez-Soler, Lung Cancer, Montefiore Medical Center, USA | 68. Dr. Eric Lander, Cancer Genomics, Broad Institute of MIT and Harvard, USA | 69. Dr. Tari A. King, Breast Cancer, Dana-Farber Cancer Institute, USA | 70. Dr. William G. Nelson, Prostate Cancer, Johns Hopkins University, USA | 71. Dr. Janusz A. Zolnierek, Cancer Epidemiology, Medical University of Silesia, Poland | 72. Dr. Mark R. Gilbert, Brain Cancer | 73. Dr. Levi Garraway, Cancer Genomics, Roche, USA | 74. Dr. Tony Hunter, Signal Transduction, Salk Institute for Biological Studies, USA | 75. Dr. Andrew T. Chan, Colorectal Cancer, Massachusetts General Hospital, USA | 76. Dr. Rakesh K. Jain, Tumor Microenvironment, Harvard Medical School, USA | 77. Dr. F. Stephen Hodi, Immunotherapy, Dana-Farber Cancer Institute, USA | 78. Dr. Jean-Charles Soria, Drug Development, Gustave Roussy Cancer Campus, France | 79. Dr. Douglas R. Lowy, HPV and Cancer, National Cancer Institute, USA | 80. Dr. Yosef Yarden, Growth Factors and Receptors, Weizmann Institute of Science, Israel | 81. Dr. Chi Van Dang, Metabolism and Cancer, The Wistar Institute, USA | 82. Dr. Gordon B. Mills, Precision Oncology, OHSU Knight Cancer Institute, USA | 83. Dr. Axel Ullrich, Signal Transduction, Max Planck Institute of Biochemistry, Germany | 84. Dr. Jean-Pierre Issa, Epigenetics and Cancer, Temple University, USA | 85. Dr. Charles G. Mullighan, Childhood Leukemia, St. Jude Children\'s Research Hospital, USA | 86. Dr. Daniel D. Von Hoff, Drug Development, Translational Genomics Research Institute, USA | 87. Dr. Pasi A. Jänne, Lung Cancer, Dana-Farber Cancer Institute, USA | 88. Dr. George D. Demetri, Sarcoma, Dana-Farber Cancer Institute, USA | 89. Dr. David A. Tuveson, Tumor Microenvironment, Cold Spring Harbor Laboratory, USA | 90. Dr. Zhi Sheng, RNA Biology and Cancer, University of Texas MD Anderson Cancer Center, USA | 91. Dr. Daniel P. Petrylak, Bladder Cancer, Yale School of Medicine, USA | 92. Dr. Robert H. Young, Pathology and Cancer, University of Texas Southwestern Medical Center, USA | 93. Dr. Ross L. Levine, Leukemia, Memorial Sloan Kettering Cancer Center, USA | 94. Dr. Jedd D. Wolchok, Immunotherapy, Memorial Sloan Kettering Cancer Center, USA | 95. Dr. Alberto Bardelli, Cancer Genomics, University of Torino, Italy | 96. Dr. Patrick G. Johnston, Cancer Research Strategy, Queen\'s University Belfast, UK | 97. Dr. Jennifer A. Doudna, CRISPR Technology, University of California, Berkeley, USA | 98. Dr. Michael F. Berger, Computational Oncology, Memorial Sloan Kettering Cancer Center, USA | 99. Dr. José Baselga, Precision Oncology, Memorial Sloan Kettering Cancer Center, USA (deceased) | 100. Dr. Martine F. Roussel, Cell Cycle and Cancer, St. Jude Children\'s Research Hospital, USA | 101. Dr. Richard M. Stone, Leukemia, Dana-Farber Cancer Institute, USA | 102. Dr. Jeffrey A. Engelman, Lung Cancer, Massachusetts General Hospital, USA | 103. Dr. Sarah-Jane Dawson, Cancer Genomics, University of Melbourne, Australia | 104. Dr. Robert A. Weinberg, Cancer Biology, Massachusetts Institute of Technology, USA | 105. Dr. Brian J. Druker, Leukemia, Oregon Health & Science University, USA |

 Related Patents

1.Combination Therapy for Treating Cancer - Patent number US9777012B2 | 2.Antibody-Mediated Therapy for Cancer - Patent number US9981062B2 | 3.Composition and Method for Treating Cancer - Patent number US10314623B2 | 4. Method of Treating Cancer Using a Combination of Small Molecules - Patent number US10635238B2 | 5. Diagnostic Test for Cancer - Patent number US10183508B2. | 6. Methods and Compositions for Treating Cancer with Anti-GITR Antibodies - Patent number US10336134B2 | 7. Methods for Treating Cancer Using a Combination of a VEGF Inhibitor and an Anti-CTLA-4 Antibody - Patent number US9687595B2 | 8. Compositions and Methods for Modulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activity - Patent number US9464157B2. | 9.Methods and Compositions for Treating Cancer with Antibodies that Bind CD47- Patent number US10336133B2 | 10. Therapeutic Compositions Comprising RNA Molecules that Target Mutant KRAS Alleles and Methods of Use Thereof - Patent number US10835157B2. | 11. Compositions and Methods for Treating Cancer with CDK4/6 Inhibitors - Patent number US9695105B2 | 12. Methods of Treating Cancer Using a Combination of a PI3K Inhibitor and a MEK Inhibitor- Patent number US10159477B2 | 13. Pharmaceutical Compositions and Methods for Treating Cancer with Antibodies that Bind LAG-3 - Patent number US10106794B2 | 14. Compositions and Methods for Treating Cancer with Small Molecule Inhibitors of Wnt/Beta-Catenin Signaling - Patent number US9808641B2 | 15. Methods and Compositions for Treating Cancer with Antibodies that Bind to TIM-3 - Patent number US10420719B2. | 16. Therapeutic Antibodies that Bind to CD19 - Patent number US9067003B2. | 17. Compositions and Methods for Targeting Tumor-Associated Macrophages - Patent number US10676367B2. | 18. Methods for Treating Cancer Using a Combination of an Anti-PD-1 Antibody and an Anti-CD137 Antibody - Patent number US10159519B2. | 19. Compositions and Methods for Treating Cancer with Small Molecule Inhibitors of TGF-beta Signaling - Patent number US10257094B2 | 20. Antibodies that Bind to CD22 and Methods of Use Thereof - Patent number US10336131B2 | 21. Methods of Treating Cancer Using a Combination of a PARP Inhibitor and a PD-1 Inhibito  - Patent number US10046660B2. | 22. Compositions and Methods for Treating Cancer with Antibodies that Bind to CD47 and PDL1 - Patent number US10669916B2 | 23. Methods of Treating Cancer Using a Combination of a CDK4/6 Inhibitor and an AKT Inhibitor - Patent number US10802117B2 | 24. Antibodies that Bind to CD19 and Methods of Use Thereof - Patent number US10720534B2 | 25. Compositions and Methods for Treating Cancer with Small Molecule Inhibitors of IDO1 - Patent number US9649361B2. | 26. Method of Treating Metastatic Melanoma with Ipilimumab - Patent number US8415411B2. | 27. Methods of Treating Cancer Using Antibodies that Bind to the Cell Surface Protein ROR1 - Patent number US10064907B2 | 28. Methods of Treating Cancer Using a Combination of a MEK Inhibitor and a PI3K Inhibitor - Patent number US10793339B2 | 29. Compositions and Methods for Treating Cancer with Antibodies that Bind to TIM3 and PD-1 - Patent number US10010314B2 | 30. Methods of Treating Cancer Using an Antibody-Drug Conjugate that Binds to Trop2 - Patent number US10224014B2. | 31. Methods of Treating Cancer Using a Combination of a CDK4/6 Inhibitor and a PD-L1 Inhibitor - Patent number US10632023B2 | 32. Methods of Treating Cancer Using a Combination of a BCL2 Inhibitor and an Anti-CD20 Antibody - Patent number US10130756B2 | 33. Compositions and Methods for Treating Cancer with a Bispecific Antibody that Binds to CD3 and HER2 - Patent number US10200370B2. | 34. Methods of Treating Cancer Using an Antibody-Drug Conjugate that Binds to Mesothelin - Patent number US10016523B2 | 35. Compositions and Methods for Treating Cancer with Antibodies that Bind to OX40 and PD-L1 - Patent number US10136968B2. | 36. Method for the Diagnosis of Cancer using Biomarkers - Patent number US9499865B2. | 37. Methods for Screening Cancer Therapeutics using Genetically Engineered Cell Lines - Patent number US10429459B2 | 38. Methods of Treating Cancer using a Combination of a PARP Inhibitor and a DNA-Damaging Agent - Patent number US10568379B2 | 39. Compositions and Methods for Treating Cancer with Antibodies that Bind to TIM3 and PD-1 - Patent number US10010314B2. | 40. Methods of Treating Cancer using a Combination of a CDK4/6 Inhibitor and a PD-L1 Inhibitor - Patent number US10632023B2. | 41. Methods of Inhibiting Cancer Cell Growth using Synthetic Lethal RNA Interference - Patent number US9228106B2. | 42. Methods for Inhibiting Cancer Cell Proliferation using an MDM2 Inhibitor - Patent number US10768976B2. | 43. Methods for the Treatment of Cancer using a Combination of an HDAC Inhibitor and a DNA-Damaging Agent - Patent number US10719919B2 | 44. Methods for Treating Cancer using a Combination of an Immunomodulatory Compound and a PD-L1 Inhibitor - Patent number US10676826B2. | 45. Compositions and Methods for the Treatment of Cancer using an Antibody-Drug Conjugate that Binds to CD79b - Patent number US10290453B2 | 46. Methods and Compositions for Targeting Cancer Cells with Immune Checkpoint Inhibitors - Patent number US10625654B2. | 47. Methods for Treating Cancer using a Combination of a CDK4/6 Inhibitor and a PI3K Inhibitor - Patent number US10412657B2. | 48. Compositions and Methods for Treating Cancer with Antibodies that Bind to PD-L1 - Patent number US10034994B2 | 49. Compositions and Methods for Targeting Cancer Cells with EGFR-Targeted Immunotoxin  - Patent number US10251217B2. | 50. Methods for Treating Cancer using a Combination of a PD-1 Inhibitor and a Chemotherapeutic Agent | 51. Methods for Treating Cancer using a Combination of an Antibody-Drug Conjugate and a CDK4/6 Inhibitor - Patent number US10719921B2 | 52. Methods for Treating Cancer using a Combination of an Anti-CD47 Antibody and a Chemotherapeutic Agent - Patent number US10462706B2 | 53. Methods and Compositions for Treating Cancer using a TGF-Beta Inhibitor - Patent number US10222733B2. | 54. Compositions and Methods for Treating Cancer using a Cancer-Specific Peptide - Patent number US10137305B2. | 55. Compositions and Methods for Treating Cancer using a Combinatorial Immunotherapy Approach - Patent number US10724295B2. | 56. Methods and Compositions for Treating Cancer using a PARP Inhibitor - Patent number US10473264B2. | 57. Compositions and Methods for Treating Cancer using a Vaccine Targeting Tumor-Associated Antigens - Patent number US10064712B2 | 58. Methods and Compositions for Treating Cancer using an EZH2 Inhibitor - Patent number US10150814B2. | 59. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD3 and a Tumor Antigen - Patent number US10228714B2. | 60. Methods and Compositions for Treating Cancer using a MEK Inhibitor - Patent number US10070920B2. | 61. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting PD-1 and a Tumor Antigen - Patent number US10291001B2 | 62. Methods and Compositions for Treating Cancer using a BET Inhibitor - Patent number US9962414B2. | 63. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD19 and CD3 - Patent number US10603761B2. | 64. Methods and Compositions for Treating Cancer using a HER3 Inhibitor - Patent number US10395025B2. | 65. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting BCMA and CD3 - Patent number US10705853B2. | 66. Methods and Compositions for Treating Cancer using an FLT3 Inhibitor - Patent number US10070917B2. | 67. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD33 and CD3 - Patent number US10137292B2 | 68. Methods and Compositions for Treating Cancer using a BRAF Inhibitor  - Patent number US10421602B2. | 69. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting EGFR and CD3 - Patent number US10137293B2 | 70. Methods and Compositions for Treating Cancer using a PI3K Inhibitor - Patent number US10272098B2. | 71. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD123 and CD3 - Patent number US10137291B2. | 72. Methods and Compositions for Treating Cancer using a CDK4/6 Inhibitor - Patent number US10171731B2. | 73. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD20 and CD3 - Patent number US10137294B2 | 74. Methods and Compositions for Treating Cancer using an IDH1 Inhibitor - Patent number US10158558B2 | 75. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting GPC3 and CD3 - Patent number US10285206B2. | 76. Methods and Compositions for Treating Cancer using a PD-1 Inhibitor - Patent number US10911622B2. | 77. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting BCMA and CD3 - Patent number US10776608B2. | 78. Methods and Compositions for Treating Cancer using an AKT Inhibitor - Patent number US10799022B2. | 79. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD38 and CD3 - Patent number US10790715B2 | 80. Methods and Compositions for Treating Cancer using an EGFR Inhibitor - Patent number US10784304B2. | 81. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting HER2 and CD3 - Patent number US10826029B2. | 82. Methods and Compositions for Treating Cancer using a TGF-beta Inhibitor - Patent number US10784305B2. | 83. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD28 and CD3 - Patent number US10783962B2 | 84. Methods and Compositions for Treating Cancer using an EZH2 Inhibitor - Patent number US10928462B2 | 85. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD47 and CD3 | 86. Methods and Compositions for Treating Cancer using an IDO Inhibitor - Patent number US10883273B2. | 87. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD20 and CD3 | 88. Methods and Compositions for Treating Cancer using a CDK4/6 Inhibitor - Patent number US10776610B2. | 89. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD19 and CD3 - Patent number US10783968B2 | 90. Methods and Compositions for Treating Cancer using a PI3K Inhibitor - Patent number US10787527B2. | 91. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD123 and CD3 - Patent number US10783963B2 | 92. Methods and Compositions for Treating Cancer using a CDK9 Inhibitor - Patent number US10851135B2 | 93. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting TROP-2 and CD3 | 94. Methods and Compositions for Treating Cancer using a PARP Inhibitor - Patent number US10928463B2. | 95. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting GPC3 and CD3 - Patent number US10851138B2. | 96. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting HER2 and CD  - Patent number US10354723B2. | 97. Methods and Compositions for Treating Cancer using a VEGF Inhibitor - Patent number US10354269B2.   | 98. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD19 and CD20 - Patent number US10374053B2. | 99. Methods and Compositions for Treating Cancer using a BRD4 Inhibitor - Patent number US10451753B2. | 100. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CEA and CD3 - Patent number US10511080B2 | 101. Methods and Compositions for Treating Cancer using a FLT3 Inhibitor - Patent number US10578434B2. | 102. Compositions and Methods for Treating Cancer using a Bispecific Antibody Targeting CD30 and CD3 - Patent number US10696989B2.\"Methods and Compositions for Treating Cancer using an Axl Inhibitor - Patent number US10704006B2. | Journals | 1.Journal of Clinical Oncology (United States): This journal was first published in 1983 and has an impact factor of 32.956 (2020) | 2.Cancer Research (United States): This journal was first published in 1941 and has an impact factor of 10.211 (2020) | 3.Annals of Oncology (Europe): This journal was first published in 1990 and has an impact factor of 18.142 (2020) | 4.Lancet Oncology (United Kingdom): This journal was first published in 2000 and has an impact factor of 36.420 (2020) | 5.Nature Reviews Cancer (United Kingdom): This journal was first published in 2001 and has an impact factor of 49.516 (2020) | 6.Cancer Cell (United States): This journal was first published in 2002 and has an impact factor of 27.407 (2020) | 7.Clinical Cancer Research (United States): This journal was first published in 1995 and has an impact factor of 11.228 (2020) | 8.Cancer Discovery (United States): This journal was first published in 2011 and has an impact factor of 34.188 (2020). | 9.Cancer (United States): This journal was first published in 1948 and has an impact factor of 6.762 (2020). | 10. Journal of the National Cancer Institute (United States): This journal was first published in 1940 and has an impact factor of 14.164 (2020) | 11. cancer Cell International (United Kingdom): This journal was first published in 2001 and has an impact factor of 5.008 (2020) | 12. Molecular Cancer (United Kingdom): This journal was first published in 2002 and has an impact factor of 13.816 (2020) | 13. Journal of Hematology & Oncology (United Kingdom): This journal was first published in 2008 and has an impact factor of 10.850 (2020). | 14. Cancer Immunology Research (United States): This journal was first published in 2013 and has an impact factor of 8.236 (2020). | 15. Journal of the National Comprehensive Cancer Network (United States): This journal was first published in 2003 and has an impact factor of 9.557 (2020). | 16. Cancer Treatment Reviews (United Kingdom): This journal was first published in 1974 and has an impact factor of 8.708 (2020). | 17. Cancer Genetics (United States): This journal was first published in 2010 and has an impact factor of 3.549 (2020). | 18. OncoImmunology (United States): This journal was first published in 2011 and has an impact factor of 7.569 (2020) | 19. Cancer Epidemiology, Biomarkers & Prevention (United States): This journal was first published in 1991 and has an impact factor of 5.508 (2020) | 20. Journal of Cancer Research and Clinical Oncology (Germany): This journal was first published in 1904 and has an impact factor of 6.221 (2020) | 21. Journal of Clinical Oncology (United States): 2021 Impact Factor - 32.956 | 22. Cancer Research (United States): 2021 Impact Factor - 10.259 | 23. Annals of Oncology (Europe): 2021 Impact Factor - 23.590 | 24. Nature Reviews Cancer (United Kingdom): 2021 Impact Factor - 56.521 | 25. Lancet Oncology (United Kingdom): 2021 Impact Factor - 44.964 | 26. Cancer Cell (United States): 2021 Impact Factor - 27.028 | 27. Clinical Cancer Research (United States): 2021 Impact Factor - 11.287 | 28. Journal of the National Cancer Institute (United States): 2021 Impact Factor - 15.885 | 29. Oncogene (United Kingdom): 2021 Impact Factor - 8.729 | 30. Cancer (United States): 2021 Impact Factor - 6.727 | 31. Journal of Clinical Oncology (United States): Impact Factor - 32.956, H-index - 433 | 32. Cancer Research (United States): Impact Factor - 10.259, H-index - 417 | 33. Annals of Oncology (Europe): Impact Factor - 23.590, H-index - 270 | 34. Nature Reviews Cancer (United Kingdom): Impact Factor - 56.521, H-index - 366 | 35. Lancet Oncology (United Kingdom): Impact Factor - 44.964, H-index - 346 | 36. Cancer Cell (United States): Impact Factor - 27.028, H-index - 244 | 37. Clinical Cancer Research (United States): Impact Factor - 11.287, H-index - 292 | 38. Journal of the National Cancer Institute (United States): Impact Factor - 15.885, H-index - 276 | 39. Oncogene (United Kingdom): Impact Factor - 8.729, H-index - 225 | 40. Cancer (United States): Impact Factor - 6.727, H-index - 29 | 41. Journal of Clinical Oncology (United States): Impact Factor - 32.956, H-index - 433 | 42. Cancer Research (United States): Impact Factor - 10.259, H-index - 417 | 43. Annals of Oncology (Europe): Impact Factor - 23.590, H-index - 270 | 44. Nature Reviews Cancer (United Kingdom): Impact Factor - 56.521, H-index - 366 | 45. Lancet Oncology (United Kingdom): Impact Factor - 44.964, H-index - 346 | 46. Cancer Cell (United States): Impact Factor - 27.028, H-index - 244 | 47. Clinical Cancer Research (United States): Impact Factor - 11.287, H-index - 292 | 48. Journal of the National Cancer Institute (United States): Impact Factor - 15.885, H-index - 276 | 49. Oncogene (United Kingdom): Impact Factor - 8.729, H-index - 225 | 50. Cancer (United States): Impact Factor - 6.727, H-index - 295 | 51. European Journal of Cancer (Europe): Impact Factor - 10.824, H-index - 213 | 52. Cancer Discovery (United States): Impact Factor - 21.731, H-index - 166 | 53. Cancer Treatment Reviews (United Kingdom): Impact Factor - 9.952, H-index - 146 | 54. Journal of Hematology & Oncology (United States): Impact Factor - 13.878, H-index - 137 | 55. Molecular Cancer (United Kingdom): Impact Factor - 6.216, H-index - 130

Sponsorship Details

International Conference on Oncology and Cancer Research warmly invite you to sponsor or exhibit of International Conference. We expect participants more than 200 numbers for our International conference will provide an opportunity to hear and meet/ads to Researchers, Practitioners, and Business Professionals to share expertise, foster collaborations and assess rising innovations across the world in the core area of mechanical engineering.

Diamond Sponsorship

1. Acknowledgement during the opening of the conference
2. Complimentary Booth of size 10 meters square
3. Four (4) delegate’s complimentary registrations with lunch
4. Include marketing document in the delegate pack
5. Logo on Conference website, Banners, Backdrop, and conference proceedings
6. One exhibition stand (1×1 meters) for the conference
7. One full cover page size ad in conference proceedings
8. Opportunities for Short speech at events
9. Opportunity to sponsors conference kit
10. Opportunity to sponsors conference lanyards, ID cards
11. Opportunity to sponsors conference lunch
12. Recognition on video ads
13. 150-word company profile and contact details in the delegate pack

Platinum Sponsorship

1. Three (3) delegate’s complimentary registrations with lunch
2. Recognition on video ads
3. Opportunity to sponsors conference lunch
4. Opportunity to sponsors conference lanyards, ID cards
5. Opportunity to sponsors conference kit
6. Opportunities for Short speech at events
7. One full page size ad in conference proceedings
8. One exhibition stand (1×1 meters) for the conference
9. Logo on Conference website, Banners, Backdrop, and conference proceedings
10. Include marketing document in the delegate pack
11. Complimentary Booth of size 10 meters square
12. Acknowledgement during the opening of the conference
13. 100-word company profile and contact details in the delegate pack

Gold Sponsorship

1. Two (2) delegate’s complimentary registrations with lunch
2. Opportunities for Short speech at events
3. Logo on Conference website, Banners, Backdrop, and conference proceedings
4. Include marketing document in the delegate pack
5. Complimentary Booth of size 10 meters square
6. Acknowledgment during the opening of the conference
7. 100-word company profile and contact details in the delegate pack
8. ½ page size ad in conference proceedings

Silver Sponsorship

1. Acknowledgment during the opening of the conference
2. One(1) delegate’s complimentary registrations with lunch
3. Include marketing document in the delegate pack
4. Logo on Conference website, Banners, Backdrop, and conference proceedings
5. ¼ page size ad in conference proceedings
6. 100-word company profile and contact details in the delegate pack

Individual Sponsorship

1. Acknowledgment during the opening of the conference
2. One(1) delegate’s complimentary registrations with lunch

Registration Fees

Exhibitions Details

Exhibit your Products & Services

Exhibit your Products & Services in International Conference on Oncology and Cancer Research. Exhibitors are welcomed from Commercial and Non-Commercial Organizations related to the conference title.

• The best platform to develop new partnerships & collaborations.
• Best location to speed up your route into every territory in the World.
• Our exhibitor booths were visited 4-5 times by 80% of the attendees during the conference.
• Network development with both Academia and Business.

Exhibitor Benefits

• Exhibit booth of Size-3X3 sqm.
• Promotion of your logo/Company Name/Brand Name through the conference website.
• Promotional video on company products during the conference (Post session and Breaks).
• Logo recognition in the Scientific program, Conference banner, and flyer.
• One A4 flyer inserts in the conference kit.
• An opportunity to sponsor 1 Poster Presentation Award.

Conference Session Tracks

Biomedical Advancements In Cancer | Cancer Care and management | Cancer Diagnostics and Staging | Cancer Drugs and Vaccines | Cancer Research and Advocacy | Cancer Treatment, Therapies and Nursing | Case Study Reports | Clinical Oncology | Coping with Cancer | Drug Design and Clinical Trials | Medical Oncology | Oncologists - Types and roles | Oncology | Oncology and its specialities | Prevention and Healthy Living | Others

Details of subject Tracks

Biomedical Advancements In Cancer: Precision Medicine Precision  drug is an approach that takes into account the unique  inheritable and molecular makeup of a person's cancer to develop targeted  curatives. This approach has led to the development of  medicines that specifically target certain mutations or proteins present in cancer cells,  perfecting treatment  issues and reducing side  goods.

Cancer Care and management : Cancer Care and  operation  Cancer is a group of  conditions characterized by the  unbridled growth and spread of abnormal cells. Cancer care and  operation involves a multidisciplinary approach to diagnose, treat, and manage the  complaint, including medical and surgical treatments, as well as  probative care and  recuperation.

Cancer diagnostics: Cancer diagnostics and staging are important  way in the process of  relating and treating cancer. Diagnosing cancer  generally involves a combination of tests, including medical history and physical examination, imaging tests(  similar asX-rays, CT  reviews, and PET  reviews), necropsies(  junking of a small sample of towel for examination under a microscope), and blood tests.

Cancer Drugs and Vaccines: Cancer medicines and Vaccines  Cancer  medicines and vaccines play a  pivotal  part in the treatment of cancer. There are several types of cancer  medicines, including chemotherapy, targeted  remedy, immunotherapy, and hormone  remedy.   Cancer  exploration and advocacy play a critical  part in  perfecting cancer  issues and quality of life for cases. exploration helps to more understand the causes and biology of cancer, as well as to develop new treatments and ameliorate being bones

Cancer research and advocacy play a critical role in improving cancer outcomes and quality of life for patients. Research helps to better understand the causes and biology of cancer, as well as to develop new treatments and improve existing ones.

 Cancer Treatment, Therapies and Nursing: Cancer Treatment, curatives and Nursing  Cancer treatment,  curatives, and nursing are critical  factors of comprehensive cancer care. There are  colorful types of cancer treatments, including surgery, radiation  remedy, chemotherapy, immunotherapy, and targeted  remedy, that can be used alone or in combination to fight cancer.

Case Study Reports: Case Study Reports  Case study reports are detailed accounts of a specific case's medical history,  opinion, treatment, and  outgrowth. They're used in medical education and  exploration to  give real- life  exemplifications of how a particular condition is managed, and to identify stylish practices and areas for  enhancement.

Clinical Oncology: Clinical oncology is a branch of medicine that focuses on the treatment and care of cancer patients. It involves the use of medical, surgical, and radiation techniques to diagnose and manage cancer. Clinical oncologists work with a team of medical professionals, including surgeons, radiation therapists, and pathologists, to develop individualized treatment plans for their patients

Dealing with a cancer diagnosis can be a challenging and emotional experience, both for the patient and their loved ones. It is normal to experience a range of emotions, including fear, anxiety, anger, and sadness. Here are some strategies that can help people cope with a cancer diagnosis

Drug Design and Clinical Trials: Drug design involves the creation of new chemical compounds, or the modification of existing compounds, to develop a new treatment for a specific disease. This process often starts with an understanding of the molecular and cellular mechanisms underlying the disease, which allows scientists to identify potential targets for drug intervention. Researchers then use various techniques, such as computer modeling and synthetic chemistry, to create and test new compounds that can interact with these targets.

Medical oncology: Medical oncology is a subspecialty of oncology that focuses on the treatment of cancer using systemic therapies, such as chemotherapy, hormonal therapy, and targeted therapy. Medical oncologists are trained to diagnose and treat all types of cancer, and they work closely with other members of the cancer care team, such as surgical oncologists, radiation oncologists, and radiologists, to provide comprehensive care to patients with cancer.

Oncologists: Oncologists are medical doctors who specialize in the treatment of cancer. There are several different types of oncologists, each with a specific role in the care of patients with cancer: Oncologists - Types and roles

Medical oncologists:  Medical oncologists specialize in the use of systemic therapies, suchoncologists specialize in the use of systemic curatives,  similar  Oncology and its fortes  Oncology is a medical specialty that deals with the opinion and treatment of cancer. Oncologists are medical croakers who have entered technical training in the treatment of cancer and are equipped to  give comprehensive care to cases with cancer.

Prevention and Healthy Living:  Prevention and healthy living are important ways in reducing the threat of developing cancer. Then are some ways to promote  forestallment and healthy living ed Practice Conference, cancer & oncology  Conference, International Conference on Nursing and oncology conference, Oncology Conference, International Conference on Pediatric Oncology,

Others: Cancer causes and threat factors Understanding the causes and threat factors for cancer can help reduce the threat of developing the complaint. Some common causes and threat factors include genetics,  life factors, exposure to certain substances, and certain medical conditions..

Targeted Audience

• Oncologists
• Cancer experimenters
• Radiologists
• Pathologists
• Medical oncologists
• Surgical oncologists
• Radiation oncologists

Targeted Countries

Afghanistan|  Albania| Algeria| Andorra | Angola| Antigua and Barbuda|  Argentina|  Armenia| Australia|  Austria|  Azerbaijan|  Bahamas|  Bahrain|  Bangladesh| Barbado|  Belarus| Belgium|  Belize|  Benin|  Bhutan| Bolivia|  Bosnia and Herzegovina|  Botswana|  Brazil|  Brunei|  Bulgaria|  Burkina Faso|  Burundi|  Cabo Verde|  Cambodia|  Cameroon|  Canada|  Central African Republic|  Chad| Chile|  China|  Colombia|  Comoros| Democratic Republic of the Congo|  Republic of the Congo| Costa Rica|  Cote d'Ivoire|  Croatia| Cuba|  Cyprus| Czech Republic|  Denmark|  Djibouti| Dominica| Dominican Republic|  Ecuador|  Egypt|  El Salvador|  Equatorial Guinea|  Eritrea| Estonia| Eswatini| Ethiopia|  Fiji|  Finland|  France| Gabon| Gambia|  Georgia| Germany|  Ghana| Greece|  Grenada| Guatemala|  Guinea|  Guinea-Bissau|  Guyana|  Haiti| Honduras|  Hungary|  Iceland|  India|  Indonesia|  Iran|  Iraq|  Ireland|  Israel|  Italy|  Jamaica|  Japan|  Jordan|  Kazakhstan| Kenya|  Kiribati|  Kosovo|  Kuwait|  Kyrgyzstan|  Laos|  Latvia|  Lebanon|  Lesotho|  Liberia| Libya|  Liechtenstein| Lithuania| Luxembourg| Madagascar|  Malawi|  Malaysia| Maldives|  Mali|  Malta|  Marshall Islands|  Mauritania|  Mauritius|  Mexico|  Micronesia|  Moldova|  Monaco|  Mongolia|  Montenegro|  Morocco|  Mozambique|  Myanmar (Burma)|  Namibia|  Nauru|  Nepal|  Netherlands|  New Zealand| Nicaragua|  Niger|  Nigeria|  North Korea|  North Macedonia|  Norway|  Oman|  Pakistan|  Palau|  Panama|  Papua New Guinea|  Paraguay|  Peru|  Philippines|  Poland|  Portugal|  Qatar|  Romania|  Russia| Rwanda|  Saint Kitts and Nevis|  Saint Lucia|  Saint Vincent and the Grenadines|  Samoa|  San Marino|  Sao Tome and Principe|  Saudi Arabia|  Senegal|  Serbia|  Seychelles|  Sierra Leone|  Singapore|  Slovakia|  Slovenia|  Solomon Islands|  Somalia|  South Africa|  South Korea|  South Sudan|  Spain| Sri Lanka|  Sudan|  Suriname|  Sweden|  Switzerland| Syria|  Taiwan|  Tajikistan|  Tanzania|  Thailand| Timor-Leste|  Togo|  Tonga|  Trinidad and Tobago| Tunisia| Turkey| Turkmenistan| Tuvalu| Uganda|  Ukraine|  United Arab Emirates|United Kingdom| United States|  Uruguay|  Uzbekistan|  Vanuatu| Vatican City| Venezuela| Vietnam| Yemen|  Zambia|  Zimbabwe.

Targeted Universities

Memorial Sloan Kettering Cancer Center, New York
MD Anderson Cancer Center, Houston
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Dana-Farber Cancer Institute, Boston
Stanford Cancer Institute, Stanford
University of Pennsylvania Abramson Cancer Center, Philadelphia
University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
City of Hope Comprehensive Cancer Center, Los Angeles
University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas
Fred Hutchinson Cancer Research Center, Seattle

Targeted Companies

• Pharmaceutical companies
• Medical device companies
• Biotech companies
• Cancer exploration associations
• Clinical trial associations.
• Academic institutions
• Technology companies

Market Analysis

The International Conference on Oncology and Cancer Research is a significant event in the  field of cancer research and treatment. This conference provides a platform for researchers, healthcare professionals, and industry experts to share their latest findings, best practices, and innovations in the field of oncology and cancer research. The market for cancer research and treatment is a rapidly growing industry, driven by advances in technology, increasing prevalence of cancer, and a growing global population. According to a recent market research report, the global cancer market is expected to reach USD 226.8 billion by 2025, growing at a CAGR of 5.6% from 2020 to 2025. The growth of the cancer market is being driven by factors such as increasing investment in cancer research, advances in technology, and the development of innovative treatments and diagnostic tools. Additionally, increasing awareness about the benefits of early detection and treatment of cancer is also driving the growth of the market. International Conference on Oncology and Cancer Research plays a crucial role in the market by providing a platform for stakeholders to network, share their research findings, and explore new business opportunities. The conference also provides a forum for attendees to discuss the latest trends and challenges in the field of oncology and cancer research, and to identify new areas for collaboration and innovation. Overall, the International Conference on Oncology and Cancer Research is an important event for the cancer research and treatment industry, and is expected to continue to play a significant role in driving the growth of the market in the coming years.